Gufic Biosciences Ltd.
NSE: GUFICBIO · Healthcare
Sector
Healthcare
Size band
Small cap
Market cap
2,877cr
P/E
56.9
ROE
12.3%
Dividend yield
0%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| Gufic Biosciences Ltd. | 18.0% | 15.0% |
What management said
11 statements on recordEarnings call · Q1 FY27 · 21 Aug 2026
- GLP-1 CMO capacity use split→30% domestic; 70% international by end of the year· end of the year
“But yes, to answer your question, we have started the CMO operations, which will, I would say, take some steam in Q2, but have further in Q3 objective would be CMO in the domestic space on maybe 30% level, but 70%, we hope at the end of the year, it would be a capacity use for the international market where Hetero and Gufic as a single channel has filed in more than 22 countries.”
- Indore capacity utilization→around 40%, 45% capacity utilization· end of the year
“And hopefully, like I said, we should end up the year on around 40%, 45% capacity utilization.”
- Revenue growth→15% year-over-year growth· this year / year-over-year
“So again, in terms of numbers, they would be part of our 15% year-over-year growth, which we always tell to people, and we're already embedded in this.”
- Revenue growth→15% to 20% year-on-year· year-on-year
“So I would say 15% to 20% is what we say we should grow year-on- year as overall, as a company, yes.”
- Revenue growth→15% to 20% bare minimum
“But 15% to 20% is what we commit to you that would be a bare minimum.”
- Revenue→around INR1100 crores· '26, '27
“Basically, if you see the expected revenue from our side for '26, '27 will in the rage of around INR1100 crores.”
- Revenue capacity with existing facilities→maximum it can touch up to INR1,600 crores with existing facilities
“And you multiply it by every 15% increase over yeart-to-years, you will able to get the revenue because INR1,100 crores into 15%, INR1,250 crores, then INR1,450 crores, then it can go up to maximum it can touch up to INR1,600 crores with existing facilities.”
- Revenue capacity without capex→INR1,600 crores to INR2,000 crores
“So totally, when I add both of them up, INR800 crores plus around 800 plus INR1,000 crores, it comes around INR1,600 crores to INR2,000 crores is the maximum capex I mean, maximum revenue, which is possible with current product basket and current legacy.”
- Revenue capacity without capex at current product mix/realization→anything around INR1,600 to INR1,800 going forward· going forward
“So answering your specific question that with no capex, keeping in mind the current product mix, keeping in the current realization per value, then we are looking at anything around INR1,600 to INR1,800 going forward.”
- Suspension and liquid formulations capacity utilization→close to 80% capacity utilization· next 3 years
“The third line is of suspension and liquid vial, which we feel that with certain contracts and certain projects, we should have suspensions and liquid formulations, which would I hope in the next 3 years, that would come close to 80% capacity utilization.”
- Indore product mix→liquid 20%; lyophilization 50%, 60%; complex injectables 20%, 30%
“So we see a product mix of around like a liquid would be 20% in Indore, lyophilization would still be around 50%, 60%, but the remaining 20% would come 20%, 30% would come from the complex injectables also.”
Taken from management commentary on the company’s earnings call and quoted verbatim. These are statements of intent made by the company, not forecasts by Bharatstox, and nothing here records whether they were met.
On air
5 calls · outcomes not trackedRecorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.
| Channel & show | Aired | Stated target | Stated stop | Outcome |
|---|---|---|---|---|
| Zee BusinessZee Business · no registration attached | 1 Sep | +11.6% | -4.8% | still open |
| Zee BusinessZee Business · no registration attached | 1 Sep | +9.3% | -4.8% | still open |
| Zee BusinessZee Business · no registration attached | 17 Aug | +49.2% | — | still open |
| Zee BusinessZee Business · no registration attached | 17 Aug | +2.6% | -1.2% | still open |
| Zee BusinessZee Business · no registration attached | 17 Aug | +2.6% | -1.2% | still open |
Shareholding
change across 4 filings| Category | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Change |
|---|---|---|---|---|---|
| Promoters | 72.5 | 72.5 | 72.5 | 72.5 | 0.0 |
| Foreign institutions | 0.5 | 0.4 | 0.4 | 0.3 | +0.2 |
| Domestic institutions | 3.7 | 3.8 | 3.7 | 3.7 | 0.0 |
| Retail & others | 23.4 | 23.3 | 23.3 | 23.5 | −0.1 |
As filed with the exchange for the periods ending Sep 25 to Jun 26.
Filings
latest 25 of 216- Certificate under SEBI (Depositories and Participants) Regulations, 20186 Oct 2026
- Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company29 Sept 2026
- Trading Window28 Sept 2026
- General Updates28 Sept 2026
- General Updates24 Sept 2026
- Credit Rating8 Sept 2026
- Intimation of Credit Rating is attached herewith8 Sept 2026
- Shareholders meeting7 Sept 2026
- Voting Results and Consolidated Scrutinizer Report of 42nd Annual General Meeting of the Company held on Friday, September 04, 2026 is attached herewith7 Sept 2026
- Shareholders meeting4 Sept 2026
- Proceedings of the 42nd Annual General Meeting of the Company held on Friday, September 04, 2026 is attached herewith4 Sept 2026
- Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Promotion and Change in Designation of Senior Management Personnel is attached herewith2 Sept 2026
- General Updates2 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates21 Aug 2026
- Copy of Newspaper Publication18 Aug 2026
- Analysts/Institutional Investor Meet/Con. Call Updates17 Aug 2026
- General Updates14 Aug 2026
- Acquisition14 Aug 2026
- Outcome of Board Meeting14 Aug 2026
- Copy of Newspaper Publication13 Aug 2026
- Record Date12 Aug 2026
- Shareholders meeting12 Aug 2026
- Copy of Newspaper Publication7 Aug 2026
- Appointment31 Jul 2026
- Outcome of Board Meeting31 Jul 2026
The 25 most recent of 216 filings we hold for GUFICBIO, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.